Trial Profile
Phase 2 Single Arm, Open-Label Study of IMC-A12 in Asymptomatic, Chemotherapy-Naive Patients With Metastatic Androgen-Independent Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Cixutumumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Eli Lilly and Company
- 14 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Feb 2013 Planned End Date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 12 Sep 2012 Planned end date changed from 1 Dec 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.